Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Indiana Alzheimer Disease Center To Host Showing Of 'The Alzheimer's Project'
The Indiana Alzheimer Disease Center will host a screening of HBO"s "The Alzheimer Project" from 6:30 to 8:30 p.m. Thursday, May 28, in the lower level auditorium of the Riley Outpatient Center, 601 West Drive, on the Indiana University-Purdue University Indianapolis campus.

Gene Network Sciences Announces Broad Cancer Collaboration With UCSF And Initial Results
Gene Network Sciences, Inc. (GNS) announced that it has entered into a research collaboration with the University of California San Francisco Cancer Center (UCSF) aimed at accelerating cancer research and drug development across several therapeutic areas. This collaboration will combine the clinical and research oncology expertise of UCSF with the computational expertise and supercomputer-driven REFS(TM) platform of GNS. Financial terms of the agreement were not disclosed.
News of the day
Analysis: How Will $155 Billion Deal With White House Really Affect Hospitals?
When hospitals agreed to accept a $155 billion pay cut from the federal government to help Washington raise money for reform efforts earlier this month, it was "to the amazement of many," the Economist reports. "How can they justify giving away such a vast sum? There are several explanations, not all of them altruistic. Taken together, they show that the industry"s leaders are bracing themselves for a period of upheaval."
Health Insurance

Atrium Medical Receives CE Mark For Its CinatraTM CoCr Coronary Stent System

Atrium Medical is pleased to announce that is has received CE Mark for a new generation Cobalt Chromium Coronary Stent System called Cinatra™. Cinatra™ is indicated for the treatment of coronary artery occlusive disease. Atrium is excited to release this best in class Cobalt Chromium Coronary Stent System that is extremely low in profile, ultra flexible, and highly deliverable. In an independent lab test, Atrium"s new Cinatra™ CoCr Stent was highlighted as having the lowest crossing profile and greatest flexibility when compared to the leading competitors.* The advanced design of the Cinatra™ CoCr Stent with its superior mechanical properties have produced excellent clinical results yielding a very low late lumen loss. Preliminary results from the CONFIRM 1 multi-center prospective trial have shown the Cinatra™ CoCr Stent to have a mean in-stent late lumen loss of 0.69 mm at 6 months. This low late lumen loss is clear evidence that Cinatra™ offers excellent clinical results and will offer cardiologists a new option when treating coronary artery disease. *Data on file at Atrium. Atrium


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009